Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report

Documenti analoghi

• Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR‐TKIs
  di: Ninomaru, Taira, et al.
  Pubblicazione: (2021)
• Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
  di: Y. Uehara, et al.
  Pubblicazione: (2024-09-01)
• Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
  di: Yingqi Xu, et al.
  Pubblicazione: (2025-12-01)
• First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
  di: Takeda, Masayuki, et al.
  Pubblicazione: (2019)
• Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors
  di: Wu, Leilei, et al.
  Pubblicazione: (2020)